ArticleFrontiers in public health2026
Burden of metabolic diseases in mainland China from 1990 to 2021: results from the global burden of disease study 2021.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Occupational disparities in chronic disease prevalence and metabolic covariation: a cross-sectional study of six occupational groups in Lanzhou.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Within the last three decades, common metabolic diseases have become a worldwide health burden, including type 2 diabetes mellitus (T2DM), hypertension, obesity, hypercholesterolemia, and metabolic dysfunction-associated steatotic liver disease (MASLD). However, trends and burdens of these metabolic diseases across age and sex in Mainland China from 1990 to 2021 remain unclear. Methods: Estimated disability-adjusted life years (DALYs) and deaths from GBD 2021 were utilized to analyze common metabolic diseases (T2DM, hypertension, obesity, hypercholesterolemia, and MASLD). Trend analyses were conducted using age-standardized DALYs (mortality) per 100,000 population and the total percentage change (TPC) between 1990 and 2021. Estimates were presented with uncertainty intervals (UI). Results: In 2021, among the five common metabolic diseases, hypertension had the highest burden (55.69 million [95% UI: 43.30-70.33] DALYs), followed by obesity (20.87 million [95% UI: 8.50-33.64] DALYs), hypercholesterolemia (18.41 million [95% UI: 10.27-27.11]), T2DM (11.47 million [95% UI: 8.83-14.70] DALYs) and MASLD (0.41 million [95% UI: 0.32-0.53] DALYs). Over the past three decades, the burden of these metabolic diseases has increased, albeit at varying magnitudes (ranging from a 0.64-fold to a 2.84-fold increase). Obesity and T2DM were the top two diseases with the highest TPC (2.84 and 1.90 respectively). The burden of DALYs and deaths, as well as their TPC in males with almost all the five common metabolic diseases was higher than that in females. In addition, the 55-74 years age group had the greatest burden of metabolic conditions. Conclusion: The burden of common metabolic diseases remained high and continued to increase in Mainland China over the past 30 years. Therefore, urgent interventions are needed to address the concerning surge in DALYs and mortality as well as the persistent age-sex disparities attributed to metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.